Edition:
India

DURECT Corp (DRRX.OQ)

DRRX.OQ on NASDAQ Stock Exchange Capital Market

1.91USD
2:29am IST
Change (% chg)

$0.02 (+1.06%)
Prev Close
$1.89
Open
$1.89
Day's High
$1.93
Day's Low
$1.86
Volume
102,679
Avg. Vol
170,137
52-wk High
$2.45
52-wk Low
$0.48

Latest Key Developments (Source: Significant Developments)

Durect Corporation Announces Positive Results From Trial Of Dur-928 In Alcoholic Hepatitis Patients
Tuesday, 12 Nov 2019 

Nov 12 (Reuters) - DURECT Corp ::DURECT CORPORATION ANNOUNCES POSITIVE RESULTS FROM THE PHASE 2A CLINICAL TRIAL OF DUR-928 IN ALCOHOLIC HEPATITIS PATIENTS IN A LATE-BREAKING PRESENTATION AT THE LIVER MEETING®.DURECT CORP - ALL PATIENTS TREATED WITH DUR-928 IN TRIAL SURVIVED 28-DAY FOLLOW-UP PERIOD.DURECT CORP - DUR-928 WAS WELL TOLERATED AT ALL DOSES TESTED.DURECT CORP - THERE WERE NO DRUG-RELATED SERIOUS ADVERSE EVENTS ON DUR-928 TRIAL.DURECT CORP - PATIENTS TREATED WITH DUR-928 HAD A STATISTICALLY SIGNIFICANT REDUCTION FROM BASELINE IN BILIRUBIN AT DAY 7 AND 28 AND MELD AT DAY 28.DURECT CORP - LILLE SCORES WERE STATISTICALLY SIGNIFICANTLY LOWER THAN THOSE FROM A WELL-MATCHED GROUP OF PATIENTS IN A CONTEMPORARY ONGOING TRIAL.  Full Article

Durect Reports Q3 Revenue of $10.8 Million
Tuesday, 5 Nov 2019 

Nov 4 (Reuters) - DURECT Corp ::ORATION ANNOUNCES THIRD QUARTER 2019 FINANCIAL RESULTS AND UPDATE OF PROGRAMS.Q3 REVENUE $10.8 MILLION.Q3 REVENUE ESTIMATE $15.7 MILLION -- REFINITIV IBES DATA.AT SEPTEMBER 30, 2019, CASH AND INVESTMENTS WERE $57.1 MILLION.  Full Article

Durect Announces Positive Data From Phase 2A Clinical Trial Of DUR-928 In Alcoholic Hepatitis
Tuesday, 17 Sep 2019 

Sept 17 (Reuters) - DURECT Corp ::DURECT ANNOUNCES POSITIVE DATA FROM ITS PHASE 2A CLINICAL TRIAL OF DUR-928 IN ALCOHOLIC HEPATITIS.DURECT CORP - DUR-928 WAS WELL TOLERATED IN ALL PATIENTS, WITH NO DRUG-RELATED SERIOUS ADVERSE EVENTS REPORTED AT ANY DOSE LEVEL.DURECT - TRIAL DATA SHOW THAT 19 PATIENTS TREATED WITH DUR-928 HAD STATISTICALLY SIGNIFICANTLY GREATER REDUCTIONS FROM BASELINE IN BILIRUBIN & MELD.DURECT - PLANNING TO MEET WITH FDA TO DISCUSS DESIGN OF NEXT DUR-928 AH CLINICAL TRIAL AS WELL AS REGULATORY PATH TO APPROVAL.  Full Article

DURECT Regains Compliance With Nasdaq Listing Rule 5550(A)(2) For Continued Listing On Nasdaq Capital Market
Wednesday, 14 Aug 2019 

Aug 13 (Reuters) - DURECT Corp ::DURECT - REGAINED COMPLIANCE WITH NASDAQ LISTING RULE 5550(A)(2) FOR CONTINUED LISTING ON NASDAQ CAPITAL MARKET & MATTER IS NOW CLOSED.  Full Article

Durect Announces Submission To FDA Of Full Response To Posimir Complete Response Letter
Thursday, 27 Jun 2019 

June 27 (Reuters) - DURECT Corp ::DURECT ANNOUNCES SUBMISSION TO FDA OF A FULL RESPONSE TO THE POSIMIR® COMPLETE RESPONSE LETTER.DURECT CORP - SUBMISSION IS INTENDED TO ADDRESS ISSUES RAISED IN CRL AND SEEKS FDA APPROVAL OF POSIMIR.DURECT - AS SUBMISSION IS INTENDED TO BE A FULL RESPONSE TO CRL, AS OPPOSED TO A NEW NDA SUBMISSION, COMPANY EXPECTS A SIX-MONTH FDA REVIEW PERIOD.  Full Article

DURECT Says Dose Escalation Committee Has Approved Commencement Of Dosing At 150 Mg Level In Severe Ah Patients
Tuesday, 18 Jun 2019 

June 18 (Reuters) - DURECT Corp ::DURECT ANNOUNCES COMPLETION OF THE 90 MG SEVERE COHORT AND DOSE ESCALATION COMMITTEE APPROVAL TO COMMENCE 150 MG DOSING IN PATIENTS WITH SEVERE ALCOHOLIC HEPATITIS (AH) IN ITS ONGOING DUR-928 PHASE 2A AH TRIAL.DURECT CORP - DOSE ESCALATION COMMITTEE (DEC) HAS APPROVED COMMENCEMENT OF DOSING AT 150 MG LEVEL IN SEVERE AH PATIENTS..  Full Article

Durect Corporation Qtrly Loss Per Share $0.04
Wednesday, 8 May 2019 

May 7 (Reuters) - DURECT Corp ::ANNOUNCES FIRST QUARTER 2019 FINANCIAL RESULTS AND UPDATE OF PROGRAMS.Q1 REVENUE $4.1 MILLION VERSUS REFINITIV IBES ESTIMATE OF $3.5 MILLION.QTRLY LOSS PER SHARE $0.04.  Full Article

Pain Therapeutics Says Sent Letter To Durect Corp Pursuant To Development And License Agreement
Saturday, 23 Mar 2019 

March 22 (Reuters) - DURECT Corp ::PAIN THERAPEUTICS - SENT LETTER TO DURECT CORP PURSUANT TO DEVELOPMENT AND LICENSE AGREEMENT.PAIN THERAPEUTICS - LETTER PROVIDED DURECT CORP WITH WRITTEN NOTICE OF TERMINATION WITHOUT CAUSE OF DLA.PAIN THERAPEUTICS INC - TERMINATION BECOMES EFFECTIVE NO LATER THAN 90 DAYS FROM MARCH 20.  Full Article

Durect Corp Reports Q4 Loss Per Share Of $0.05
Friday, 8 Mar 2019 

March 7 (Reuters) - DURECT Corp ::ORATION ANNOUNCES FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND UPDATE OF PROGRAMS.Q4 REVENUE $3.6 MILLION VERSUS REFINITIV IBES ESTIMATE OF $3.8 MILLION.QTRLY LOSS PER SHARE $0.05.  Full Article

Durect Plans To Submit To FDA A Full Response To The Posimir Complete Response Letter In H1 2019
Wednesday, 27 Feb 2019 

Feb 27 (Reuters) - DURECT Corp ::DURECT ANNOUNCES PLANS TO SUBMIT TO FDA A FULL RESPONSE TO THE POSIMIR® COMPLETE RESPONSE LETTER.DURECT - SUBMISSION WILL REQUEST FDA APPROVAL OF POSIMIR BASED ON WHAT COMPANY AND ITS ADVISORS BELIEVE IS ADEQUATE EVIDENCE OF BOTH SAFETY AND EFFICACY..DURECT CORP - EXPECTS TO MAKE SUBMISSION IN FIRST HALF OF 2019.  Full Article